Genelux Investor Presentation Deck
Olvi-Vec-Primed Immunochemotherapy Overcomes "Refractoriness"
Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines
(mos)
PFS
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
●
●
●
Overall Survival: 23.2 Months
Failed 10 Prior Lines
●
8.7
GENELUX
15B-01:
Stage IIIB papillary
serous
ECOG: 0
BRCA negative
PD-L1 negative
R# 1: taxol + carbo
ÏÏÏ
3.7 4.0
3.0
1.4
R#2: Doxil + carbo
12.0
R#3: Avastin
R#4: cisplatin + Gemzar
10.9
Regimens
R#5: Tamoxifen + Provera + etoposide
R#7: etoposide
5.4
R#8: topotecan
R#6: Tamoxifen + Megace + Femara
1.4
R#9: carbo
9.3
15.5
R#10: Rubraca
R#11: Olvi-Vec + C/Bev
(mos)
PFS
12
10
8
Overall Survival: 12.3 Months
Failed 6 Prior Lines
6
4
2
0
●
8.1
●
●
●
15B-15:
Stage IIIB high-
grade serous
ECOG: 0
R#1: carbo + taxol
BRCA negative
PD-L1 negative
6.1
5
R#2: olaparib + cediranib
R# 3: Gemzar + IMGN853
3
R#4: Doxil+Bev
R#5: topotecan
2
Regimens
2
10.3
R#6: cisplatin + Gemzar
Olvi-Vec-primed C/Bev
(mos)
PFS
14.0
Overall Survival: 15.7 Months
Failed 7 Prior Lines
12.0
●
10.0
8.0
6.0
4.0
2.0
0.0
●
●
15B-17:
Stage IIIC high-
grade serous
ECOG: 1
BRCA negative
6.5
ÏÏÏ
3.0
3.0
6.0
R#1: Carbo+ Gemzar/Doxil
R#2: Niraparib
R#3: Cytoxan + Bev
R#4: Taxol + Bev
6.0
R#5: Pembrolizumab
Regimens
1.8
R#6: SC003
0.3
11.5
R#7: Carbo + Doxil
R#8: Olvi-Vec-primed C/Bev
15View entire presentation